CHINA CARDIOVASCULAR ULTRASOUND MARKET FORECAST 2022-2028

The China cardiovascular ultrasound market is set to record a CAGR of 6.03% during the forecast period, 2022-2028, and set to project revenue of $124.58 million by 2028.

The fast-paced economic progress has impacted lifestyle changes in China. Accordingly, the risk of cardiovascular diseases (CVDs) has increased due to lifestyle changes, a surging aging population, and urbanization. CVD incidences have been on a constant rise and are a major public health issue in the country.

To know more about this report, request a free sample copy

Therefore, the rising incidences of cardiovascular diseases and the increasing geriatric population are among the significant growth drivers of the China cardiovascular ultrasound market. As per the United Nations Department of Economic and Social Affairs, in 2019, over 11% of China’s population were aged 65 and above. Also, the fast growth rate of the aging population is attributed to the long run of the country’s one-child policy and the increasing healthcare facilities.

The aging process is associated with decreased vascular compliance and increased vascular rigidity. As a result, elderly patients are highly vulnerable to cardiovascular disorders like venous thromboembolism (VTE), aortic disease, and peripheral arterial disease (PAD).

Furthermore, lower extremity atherosclerotic disease (LEAD) is common among the middle-aged and senior population in the country. One of the primary causes of LEAD is atherosclerosis. In addition, Ischemic Heart Disease (IHD) and cerebrovascular disease are present in 25% and 30% of patients with LEAD, respectively. According to the China National Stroke Prevention Project, 84,880 residents aged around 40 years from 31 autonomous regions, municipalities, and provinces of mainland China underwent carotid ultrasonography. Such factors direct the China cardiovascular ultrasound market growth.

The China cardiovascular ultrasound market scope includes type, display, end-user, and technology. The type segment includes transesophageal echocardiography, fetal echocardiography, transthoracic echocardiography, and other types.

Transthoracic echocardiography is a heart test and the most common echocardiogram type done on those suffering from heart conditions. Sound waves are used to create computerized outlines of the heart and its attached blood vessels. Also, it has become the most important, non-invasive screening tool for pulmonary hypertension due to its vast availability, cost-effectiveness, and safety in enabling repeated use without ionizing radiation exposure. Additionally, it aids in diagnosing pericardial disease, enabling the evaluation of the physiologic consequences and structural assessment of the heart. Moreover, the most common reason for an echocardiogram is the left ventricular function assessment.

Fetal echocardiography is similar to an ultrasound. It is done in the second trimester and used to examine the function and structure of the unborn child’s heart. Also, the sound waves used in the test echo off the structure of the fetus’s heart, and the machine analyses the sound waves, thereby creating an image of the heart. Besides, it is considered essential since it helps doctors in detecting problems and provide timely treatment.

Furthermore, intracardiac echocardiography is used to get images of the intracardiac structures and acts as an alternative to the transesophageal approach, which needs anesthesiology and is semi-invasive. It is used to determine intracardiac thrombus, detect life-threatening complications of transseptal puncture, get the visualization of the coronary sinus, and diagnose intracardiac masses.

Some of the leading companies in the China cardiovascular ultrasound market are Telemed Ultrasound Medical Systems, Philips Healthcare, Siemens Healthineers, Mindray Medical International Limited, Samsung Medison Co Ltd, etc.

Mindray is healthcare technology, innovation, and development company. It provides products for defibrillation systems, hematology, anesthesia, AED, radiology, ultrasound, and patient monitoring. The company has a presence in the Middle East, Asia-Pacific, Europe, Latin America, and North America. It is headquartered in Shenzhen, China.

One of its key products, M9, provides advanced signal transmission and reception processors and offers highly sensitive and accurate echo detection.

Report Synopsis

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.